AR 03Alternative Names: AR03
Latest Information Update: 06 Aug 2015
At a glance
- Originator Arbor Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 05 Dec 2011 Phase-II clinical trials in Undefined indication in USA (unspecified route)